Eğitim Bilgileri
2018 - Devam Ediyor
2018 - Devam EdiyorTıpta Yandal Uzmanlık
İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Abd- Tıbbi Onkoloji Bd, Türkiye
2014 - 2018
2014 - 2018Tıpta Uzmanlık
İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Abd, Türkiye
Yabancı Diller
B2 Orta Üstü
B2 Orta Üstüİngilizce
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Endokrinoloji ve Metabolizma Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2018 - Devam Ediyor
2018 - Devam EdiyorAraştırma Görevlisi Dr.
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
2014 - 2018
2014 - 2018Araştırma Görevlisi Dr.
İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Abd
Makaleler
Tümü (18)
SCI-E, SSCI, AHCI (16)
SCI-E, SSCI, AHCI, ESCI (18)
ESCI (2)
Scopus (18)
TRDizin (2)
2022
20221. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
EROL C., ŞENDUR M. A. N., Bilgetekin I., BAYIR GARBİOĞLU D., HAMDARD J., Akbas S., et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
, cilt.18, sa.9, ss.347-353, 2022 (SCI-Expanded, Scopus)
2022
20222. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report
Samanci N. S., Guliyev M., Degerli E., Celik E., Turna Z. H.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
, cilt.18, sa.3, ss.792-794, 2022 (SCI-Expanded, Scopus)
2022
20223. A single center's experience of the extrapulmonary neuroendocrine carcinomas
ÇELİK E., ŞENGÜL SAMANCI N., Derin S., Bedir S., DEĞERLİ E., ORUÇ K., et al.
NORTHERN CLINICS OF ISTANBUL
, cilt.9, sa.1, ss.35-40, 2022 (ESCI, Scopus, TRDizin)
2022
20224. The Relationship Between Symptom Severity and Caregiver Burden in Cancer Patients Under Palliative Care: A Cross-Sectional Study
ÇELİK E., ASLAN M. Ş., ŞENGÜL SAMANCI N., Karadag M., Saglam T., Celik Y. C., et al.
JOURNAL OF PALLIATIVE CARE
, cilt.37, sa.1, ss.48-54, 2022 (SCI-Expanded, SSCI, Scopus)
2021
20215. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency
ÇELİK E., ŞENGÜL SAMANCI N., Karadag M., Demirci N. S., Cikman D. I., Derin S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.27, sa.7, ss.1665-1673, 2021 (SCI-Expanded, Scopus)
2021
20216. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID-19 patients with malignancy: A single-center experience
Degerli E., Derin S., Oruc K., Sengul Samanci N., Bedir S., Celik E., et al.
JOURNAL OF MEDICAL VIROLOGY
, cilt.93, sa.10, ss.5839-5845, 2021 (SCI-Expanded, Scopus)
2021
20217. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer
Sengul S., Cikman D., Oruc K., Bedir S., Çelik E., Degerli E., et al.
TUMORI J
, cilt.107, sa.4, ss.304-310, 2021 (SCI-Expanded, Scopus)
2021
20218. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus)
2021
20219. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection
ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., TUTAR O., SAMANCI C., VELİDEDEOĞLU M., et al.
JOURNAL OF SURGICAL ONCOLOGY
, cilt.123, sa.8, ss.1757-1763, 2021 (SCI-Expanded, Scopus)
2020
202010. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation
Sengul S., Yılmaz U., Bedir S., Ozgur Y., Oruc K., Durak S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.8, ss.2042-2046, 2020 (SCI-Expanded, Scopus)
2020
202011. Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas
Ozkaya H. M., Sahin S., Korkmaz O. P., Durcan E., Sahin H. R., Celik E., et al.
GROWTH HORMONE & IGF RESEARCH
, cilt.55, 2020 (SCI-Expanded, Scopus)
2020
202012. Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient
Sengul Samanci N., Celik E., Akovali B., Sager S., Demirelli F. H.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.8, ss.2031-2033, 2020 (SCI-Expanded, Scopus)
2020
202013. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., EROL B. Ç., Bicki E., ORUÇ K., et al.
Melanoma research
, cilt.30, sa.5, ss.477-483, 2020 (SCI-Expanded, Scopus)
2020
202014. The most cited articles on cancer immunotherapy: An update study
ÇELİK E., DOKUR M.
JOURNAL OF BUON
, cilt.25, sa.2, ss.1178-1192, 2020 (SCI-Expanded, Scopus)
2020
202015. Optic Neuritis Related to Atezolizumab Treatment in a Patient With Metastatic Non-Small-Cell Lung Cancer
Samanci N., Ozan T., Celik E., Demirelli F. H.
JCO ONCOLOGY PRACTICE
, cilt.16, sa.2, ss.96-99, 2020 (SCI-Expanded, Scopus)
2020
202016. Comparison of Attention for Cancer Research on Social Media Versus Academia: An Altmetric Score Analysis
ÇELİK E., DOKUR M., Borku Uysal B., ŞENGÜL SAMANCI N., DEMİRELLİ F. H.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.30, sa.1, ss.32-42, 2020 (SCI-Expanded, Scopus, TRDizin)
2020
202017. The top 100 cited articles in lung cancer - a bibliometric analysis
ŞENGÜL SAMANCI N., ÇELİK E.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
, cilt.24, sa.1, ss.17-28, 2020 (ESCI, Scopus)
2018
201818. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up
Celik E., Ozkaya H. M., Poyraz B. C., Saglam T., Kadioglu P.
ENDOCRINE
, cilt.62, sa.3, ss.692-700, 2018 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2019
20191. Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience
Samanci N., Oruc K., Bedir S., Celik E., Degerli E., Derin S., et al.
Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, (Özet Bildiri)
2015
20152. IMPACT OF INITIAL CHEMOTHERAPY RESPONSE AND PRETRANSPLANT DISEASE STATUS BEFORE AUTOLOGOUS TRANSPLANTATION ON SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA
Yalniz F., Elverdi T., Celik E., Berk S., Erdogan I., Salihoglu A., et al.
20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.744, (Özet Bildiri)
Desteklenen Projeler
2016 - 2018
2016 - 2018Prolaktinoma ve akromegali hastalarında dopamin agonistleri ile dürtüsellik, anksiyete, depresyon arasındaki ilişkinin prospektif olarak incelenmesi
Yükseköğretim Kurumları Destekli Proje , BAP Doktora
KADIOĞLU P. (Yürütücü), ÇELİK E., ÖZKAYA H. M., KESKİN F. E., POYRAZ B. Ç.